<?xml version="1.0" encoding="iso-8859-1" ?>
<rss version="2.0" xmlns:s="http://resources.bnet.com/">
<channel>
	<title><![CDATA[Merck & Co. Inc. | Company News & Executive Profiles - MRK | BNET]]></title>
	<link><![CDATA[http://resources.bnet.com/topic/merck+%26+co.+inc..html?i=11]]></link>
	<description><![CDATA[Latest company news & analysis, recent events, stock quotes, earning call transcripts, with profiles and descriptions of top business executives for Merck & Co. Inc.]]></description>
	<s:counts start="0" returned="10" found="2215" />
	<language>en-us</language>
	<item>
		<title><![CDATA[Can Novartis Win Race to Launch First Oral Drug for MS?]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10005592/can-novartis-win-race-to-launch-first-ms-oral-drug/]]></link>
		<description><![CDATA[Novartis AG is jockeying with German drug maker Merck KgaA to deliver the first disease-modifying treatment for relapsing forms of multiple sclerosis that can be taken orally, rather than by infusion or injection. Fingolimod could finally move ahead in the race to market, as the FDA rejected Merck's new drug...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_bnet.gif" type="image/gif" />
		<pubDate>Thu, 03 Dec 2009 10:25:11 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/merck+%2526+co.+inc..html"><![CDATA[Merck & Co. Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/novartis+ag.html"><![CDATA[Novartis AG]]></category>
		<category domain="http://resources.bnet.com/topic/microsoft+corp..html"><![CDATA[Microsoft Corp.]]></category>
		<category domain="http://resources.bnet.com/topic/federal+government.html"><![CDATA[Federal Government]]></category>
		<category domain="http://resources.bnet.com/topic/tablets.html"><![CDATA[Tablets]]></category>
		<category domain="http://resources.bnet.com/topic/notebooks.html"><![CDATA[Notebooks]]></category>
		<category domain="http://resources.bnet.com/topic/government.html"><![CDATA[Government]]></category>
		<category domain="http://resources.bnet.com/topic/hardware.html"><![CDATA[Hardware]]></category>
		<category domain="http://resources.bnet.com/topic/notebooks+%2526+tablets.html"><![CDATA[Notebooks & Tablets]]></category>
		<category domain="http://resources.bnet.com/topic/david+phillips.html"><![CDATA[David Phillips]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MRK</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MSFT</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">NVS</category>
		<category domain="tickers">MRK,MSFT,NVS</category>
	</item>
	<item>
		<title><![CDATA[Supreme Court Chutzpah: Merck Says It Should Have Been Sued Sooner on Vioxx]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10005569/supreme-court-chutzpah-merck-says-it-should-have-been-sued-sooner-on-vioxx/]]></link>
		<description><![CDATA[Merck MRK got a rough ride at the U.S. Supreme Court on Monday. The justices ridiculing the companyâ€™s argument that investors in its stock should have sued the company earlier over its misrepresentations about Vioxx even though they would not have had the evidence for their suits to succeed at...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_bnet.gif" type="image/gif" />
		<pubDate>Tue, 01 Dec 2009 08:18:12 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/merck+%2526+co.+inc..html"><![CDATA[Merck & Co. Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/u.s.+supreme+court.html"><![CDATA[U.S. Supreme Court]]></category>
		<category domain="http://resources.bnet.com/topic/financial+accounting.html"><![CDATA[Financial Accounting]]></category>
		<category domain="http://resources.bnet.com/topic/investment.html"><![CDATA[Investment]]></category>
		<category domain="http://resources.bnet.com/topic/finance.html"><![CDATA[Finance]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MRK</category>
		<category domain="tickers">MRK</category>
	</item>
	<item>
		<title><![CDATA[Merck - Zetia: Matt Herper nails the coffin shut]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/news-analysis/merck-zetia-matt-herper-nails/21984/]]></link>
		<description><![CDATA[Marc Pfeffer, a cardiologist at Brigham & Women's Hospital in Boston, points to another factor that contributed to Zetia's rise: the often misplaced faith doctors have in improved lab test results. "When you have a lab value that reinforces your belief in a drug, you feel good about what you're...]]></description>
		<s:doctype><![CDATA[News items]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_bnet.gif" type="image/gif" />
		<pubDate>Thu, 26 Nov 2009 14:25:16 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/lab.html"><![CDATA[Lab]]></category>
	</item>
	<item>
		<title><![CDATA[Merck Triumphs in Defense of Osteoporosis Drug ... for Now]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F175394-merck-triumphs-in-defense-of-osteoporosis-drug-for-now%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[The Burrill Report submits:  Merck MRK has triumphed in the second of three key cases alleging its osteoporosis drug, Fosamax, can cause osteonecrosis of the jaw. The victory comes just two months after a similar case resulted in a mistrial when its jury deadlocked. In a summary judgment for...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Thu, 26 Nov 2009 12:27:55 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/the+burrill+report.html"><![CDATA[The Burrill Report]]></category>
		<category domain="http://resources.bnet.com/topic/merck+%2526+co.+inc..html"><![CDATA[Merck & Co. Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MRK</category>
		<category domain="tickers">MRK</category>
	</item>
	<item>
		<title><![CDATA[Merck cholesterol scrips drop as Niaspan rises]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/news-analysis/merck-cholesterol-scrips-drop-niaspan/21831/]]></link>
		<description><![CDATA[Last week, all eyes were on Merck's cholesterol drugs. How did Zetia do in that much-anticipated study pitting it against Abbott Laboratories' Niaspan treatment? Well, the American Heart Association meeting has come and gone, and while the study favored Niaspan, the even-handed media coverage pointed out the trial's shortcomings as well...]]></description>
		<s:doctype><![CDATA[News items]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_bnet.gif" type="image/gif" />
		<pubDate>Wed, 25 Nov 2009 06:51:04 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/merck+%2526+co.+inc..html"><![CDATA[Merck & Co. Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/dow+jones+%2526+company+inc..html"><![CDATA[Dow Jones & Company Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/cholesterol.html"><![CDATA[Cholesterol]]></category>
		<category domain="http://resources.bnet.com/topic/abbott+laboratories+inc..html"><![CDATA[Abbott Laboratories Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">ABT</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">DJ</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MRK</category>
		<category domain="tickers">ABT,DJ,MRK</category>
	</item>
	<item>
		<title><![CDATA[Merck Serono to Spend $225 Million on New Beijing R&D Center]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F175259-merck-serono-to-spend-225-million-on-new-beijing-r-d-center%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[ChinaBio Today submits:  Merck Serono, a division of Germany&#8217;s Merck KGaA MRK, will build a global R&D center in Beijing, China, spending $225 million over the next four years. The center, which will eventually house 200 employees, will be the fourth major R&D center for the company. The Beijing...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Wed, 25 Nov 2009 04:09:47 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/china.html"><![CDATA[China]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/chinabio+today.html"><![CDATA[ChinaBio Today]]></category>
		<category domain="http://resources.bnet.com/topic/merck+%2526+co.+inc..html"><![CDATA[Merck & Co. Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MRK</category>
		<category domain="tickers">MRK</category>
	</item>
	<item>
		<title><![CDATA[Merck prevails in second Fosamax case]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/news-analysis/merck-prevails-fosamax/21698/]]></link>
		<description><![CDATA[Two down and one to go. Merck just won summary judgment in one of the three closely watched Fosamax liability suits. It's the second Fosamax case to go down; in September, the first suit to go to court ended in a mistrial. It's expected to be retried, but a date...]]></description>
		<s:doctype><![CDATA[News items]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_bnet.gif" type="image/gif" />
		<pubDate>Tue, 24 Nov 2009 10:21:11 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/merck+%2526+co.+inc..html"><![CDATA[Merck & Co. Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/plaintiff.html"><![CDATA[plaintiff]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MRK</category>
		<category domain="tickers">MRK</category>
	</item>
	<item>
		<title><![CDATA[Value Investors Know Insmed's Cash Wealth Offers No Margin of Safety]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F174991-value-investors-know-insmed-s-cash-wealth-offers-no-margin-of-safety%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Saj Karsan submits: As value investors, we often foray into areas of investment that nobody else will. Current earnings may be poor, the outlook uncertain, and the returns not expected for several years. In return for these sacrifices, we require one attribute on which we are unwilling to compromise: A...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Tue, 24 Nov 2009 02:29:05 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/saj+karsan.html"><![CDATA[Saj Karsan]]></category>
		<category domain="http://resources.bnet.com/topic/insmed+inc..html"><![CDATA[Insmed Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/merck+%2526+co.+inc..html"><![CDATA[Merck & Co. Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">INSM</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MRK</category>
		<category domain="tickers">INSM,MRK</category>
	</item>
	<item>
		<title><![CDATA[Merck KGaA plans €150m clinical R&D centre in China]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/news-analysis/merck-kgaa-plans-150m-clinical/21623/]]></link>
		<description><![CDATA[The facility, which will be operated by Merck Serono, will manage the German drugmaker's clinical trial operations in the country and, according to spokesman Gangolf Schrimpf, will build on its existing presence. Dr Schrimpf told in-PharmaTechnologist that: "[Merck} is keen to further develop in-house clinical research capacity in emerging markets,"...]]></description>
		<s:doctype><![CDATA[News items]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_bnet.gif" type="image/gif" />
		<pubDate>Tue, 24 Nov 2009 02:09:40 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/merck+%2526+co.+inc..html"><![CDATA[Merck & Co. Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/capacity.html"><![CDATA[capacity]]></category>
		<category domain="http://resources.bnet.com/topic/serono+s.a..html"><![CDATA[Serono S.A.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MRK</category>
		<category domain="tickers">MRK</category>
	</item>
	<item>
		<title><![CDATA[Merck - Vioxx: Adverse Heart Effects May Have Been Identified Years Earlier]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/news-analysis/merck-vioxx-adverse-heart-effects/21596/]]></link>
		<description><![CDATA[    CHICAGO – Clinical trial data indicated an association between the anti-inflammatory medication rofecoxib and cardiovascular risk as early as December 2000, before the product was taken off the market in September 2004, according to a report in the November 23 issue of  Archives of Internal...]]></description>
		<s:doctype><![CDATA[News items]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_bnet.gif" type="image/gif" />
		<pubDate>Mon, 23 Nov 2009 16:59:35 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/data.html"><![CDATA[data]]></category>
		<category domain="http://resources.bnet.com/topic/product.html"><![CDATA[product]]></category>
		<category domain="http://resources.bnet.com/topic/trial.html"><![CDATA[trial]]></category>
		<category domain="http://resources.bnet.com/topic/author.html"><![CDATA[author]]></category>
		<category domain="http://resources.bnet.com/topic/clinical+trial.html"><![CDATA[Clinical Trial]]></category>
	</item>
</channel>
</rss>
